This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Feigelson, H. S. Articles by Henderson, B. E. Search for Related Content PubMed PubMed Citation Articles by Feigelson, H. S. Articles by Henderson, B. E.

Cytochrome P450c17 Gene (CYP17) Polymorphism Predicts Use of Hormone Replacement Therapy¹

Departments of Preventive Medicine [H. S. F., R. M-C., M. C. P., B. E. H.] and Urology [G. A. C.], University of Southern California School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California 90033-0800, and Cancer Etiology Program, Cancer Research Center of Hawaii, University of Hawaii Honolulu, Honolulu, Hawaii 96813 [L. N. K., A. M. Y. N., L. L.]

We investigated whether a polymorphism in the cytochrome P450c17 gene (CYP17), which is associated with higher endogenous hormone levels, influences the use of hormone replacement therapy (HRT). The study included 749 postmenopausal women ages 44–75 years at baseline randomly selected from a larger multiethnic cohort. African-American, Japanese, Latina, and white women were included in the study. Women who carry the CYP17 A2/A2 genotype were about half as likely as women with the A1/A1 genotype to be current HRT users (odds ratio = 0.52; 95% confidence interval, 0.31–0.86). This association was present in all four racial/ethnic groups and for women above and below the median weight of 150 pounds. These findings suggest that the actual risk of breast cancer associated with HRT use may be higher than previously reported.

This article has been cited by other articles:

				Y. Chen, M. D. Gammon, S. L. Teitelbaum, J. A. Britton, M. B. Terry, S. Shantakumar, S. M. Eng, Q. Wang, I. Gurvich, A. I. Neugut, et al. Estrogen-biosynthesis gene CYP17 and its interactions with reproductive, hormonal and lifestyle factors in breast cancer risk: results from the Long Island Breast Cancer Study Project Carcinogenesis, April 1, 2008; 29(4): 766 - 771. [Abstract] [Full Text] [PDF]

				P. T. Campbell, L. Edwards, J. R. McLaughlin, J. Green, H. B. Younghusband, and M. O. Woods Cytochrome P450 17A1 and Catechol O-Methyltransferase Polymorphisms and Age at Lynch Syndrome Colon Cancer Onset in Newfoundland Clin. Cancer Res., July 1, 2007; 13(13): 3783 - 3788. [Abstract] [Full Text] [PDF]

				T. R. Rebbeck, A. B. Troxel, A. H. Walker, S. Panossian, S. Gallagher, E. G. Shatalova, R. Blanchard, S. Norman, G. Bunin, A. DeMichele, et al. Pairwise Combinations of Estrogen Metabolism Genotypes in Postmenopausal Breast Cancer Etiology Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 444 - 450. [Abstract] [Full Text] [PDF]

				S. E. McCann, J. Wactawski-Wende, K. Kufel, J. Olson, B. Ovando, S. N. Kadlubar, W. Davis, L. Carter, P. Muti, P. G. Shields, et al. Changes in 2-Hydroxyestrone and 16{alpha}-Hydroxyestrone Metabolism with Flaxseed Consumption: Modification by COMT and CYP1B1 Genotype Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 256 - 262. [Abstract] [Full Text] [PDF]

				H. S. Kok, N. C. Onland-Moret, K. M. van Asselt, C. H. van Gils, Y. T. van der Schouw, D. E. Grobbee, and P. H.M. Peeters No association of estrogen receptor {alpha} and cytochrome P450c17{alpha} polymorphisms with age at menopause in a Dutch cohort Hum. Reprod., February 1, 2005; 20(2): 536 - 542. [Abstract] [Full Text] [PDF]

				L. Sharp, A. H. Cardy, S. C. Cotton, and J. Little CYP17 Gene Polymorphisms: Prevalence and Associations with Hormone Levels and Related Factors. A HuGE Review Am. J. Epidemiol., October 15, 2004; 160(8): 729 - 740. [Abstract] [Full Text] [PDF]

				C. Ntais, A. Polycarpou, and J. P. A. Ioannidis Association of the CYP17 Gene Polymorphism with the Risk of Prostate Cancer: A Meta-Analysis Cancer Epidemiol. Biomarkers Prev., February 1, 2003; 12(2): 120 - 126. [Abstract] [Full Text] [PDF]

				I. Gorai, K. Tanaka, M. Inada, H. Morinaga, Y. Uchiyama, R. Kikuchi, O. Chaki, and F. Hirahara Estrogen-Metabolizing Gene Polymorphisms, But Not Estrogen Receptor-{alpha} Gene Polymorphisms, Are Associated with the Onset of Menarche in Healthy Postmenopausal Japanese Women J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 799 - 803. [Abstract] [Full Text] [PDF]

				S. E. McCann, K. B. Moysich, J. L. Freudenheim, C. B. Ambrosone, and P. G. Shields The Risk of Breast Cancer Associated with Dietary Lignans Differs by CYP17 Genotype in Women J. Nutr., October 1, 2002; 132(10): 3036 - 3041. [Abstract] [Full Text] [PDF]

				C. J. Gruber, W. Tschugguel, C. Schneeberger, and J. C. Huber Production and Actions of Estrogens N. Engl. J. Med., January 31, 2002; 346(5): 340 - 352. [Full Text] [PDF]

				C. A. Haiman, S. E. Hankinson, G. A. Colditz, D. J. Hunter, and I. De Vivo A Polymorphism in CYP17 and Endometrial Cancer Risk Cancer Res., May 1, 2001; 61(10): 3955 - 3960. [Abstract] [Full Text]

				R. McKean-Cowdin, H. S. Feigelson, M. C. Pike, G. A. Coetzee, L. N. Kolonel, and B. E. Henderson Risk of Endometrial Cancer and Estrogen Replacement Therapy History by CYP17 Genotype Cancer Res., February 1, 2001; 61(3): 848 - 849. [Abstract] [Full Text]

				H. S. Feigelson, R. McKean-Cowdin, G. A. Coetzee, D. O. Stram, L. N. Kolonel, and B. E. Henderson Building a Multigenic Model of Breast Cancer Susceptibility: CYP17 and HSD17B1 Are Two Important Candidates Cancer Res., January 1, 2001; 61(2): 785 - 789. [Abstract] [Full Text]

				K. Mitrunen, N. Jourenkova, V. Kataja, M. Eskelinen, V.-M. Kosma, S. Benhamou, H. Vainio, M. Uusitupa, and A. Hirvonen Steroid Metabolism Gene CYP17 Polymorphism and the Development of Breast Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2000; 9(12): 1343 - 1348. [Abstract] [Full Text]

				A. B. Spurdle, J. L. Hopper, G. S. Dite, X. Chen, J. Cui, M. R. E. McCredie, G. G. Giles, M. C. Southey, D. J. Venter, D. F. Easton, et al. CYP17 Promoter Polymorphism and Breast Cancer in Australian Women Under Age Forty Years J Natl Cancer Inst, October 18, 2000; 92(20): 1674 - 1681. [Abstract] [Full Text] [PDF]

				T. Habuchi, Z. Liqing, T. Suzuki, R. Sasaki, N. Tsuchiya, H. Tachiki, N. Shimoda, S. Satoh, K. Sato, Y. Kakehi, et al. Increased Risk of Prostate Cancer and Benign Prostatic Hyperplasia Associated with a CYP17 Gene Polymorphism with a Gene Dosage Effect Cancer Res., October 1, 2000; 60(20): 5710 - 5713. [Abstract] [Full Text]